Literature DB >> 30522616

The clinical utility of cycle of threshold value of GeneXpert MTB/RIF (CBNAAT) and its diagnostic accuracy in pulmonary and extra-pulmonary samples at a tertiary care center in India.

Ashish K Prakash1, B Datta2, J P Tripathy3, N Kumar4, P Chatterjee2, A Jaiswal2.   

Abstract

BACKGROUND: There are knowledge gaps in the in-depth analysis of the most promising and robust diagnostic tool, GeneXpert MTB/RIF (CBNAAT). The cycle of threshold (CT) value of the CBNAAT test and its clinical implications has not been explored much. AIMS AND
OBJECTIVES: The study aimed at (a) estimating the diagnostic accuracy and incremental yield of Xpert MTB/RIF in various specimens (b) establishing the association between CT value category (high, medium, low, very low) and culture time-to-positivity (TTP).
METHODS: A total of 1000 samples, both pulmonary and extra-pulmonary were collected from presumptive TB cases in a large tertiary care hospital. Sensitivity and specificity of CBNAAT was calculated with culture as the gold standard. The association of CT value with culture TTP was also studied.
RESULTS: The overall sensitivity of CBNAAT was 88.5%, with bronchial washing specimen being the most sensitive (92.3%) and pleural fluid being the least (66.7%). In smear negative individuals, the sensitivity of CBNAAT was 80.9%. The additional yield of CBNAAT over smear microscopy was 10.9%. It was observed that as we move from high to very low CT category, culture positivity decreases significantly (p<0.001), whereas time taken for culture growth increases (p<0.001).
CONCLUSION: CBNAAT is a robust test for accurate diagnosis of tuberculosis both pulmonary and extra-pulmonary, smear negative as well, especially in resource-limited settings. The correlation between CT value and culture TTP has potential in predicting bacillary load, though further studies are required.
Copyright © 2018 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CBNAAT; Sputum culture; TB diagnostics

Mesh:

Year:  2018        PMID: 30522616     DOI: 10.1016/j.ijtb.2018.05.021

Source DB:  PubMed          Journal:  Indian J Tuberc        ISSN: 0019-5707


  5 in total

1.  Xpert MTB/RIF Ultra versus Xpert MTB/RIF for diagnosis of tuberculous pleural effusion: A systematic review and comparative meta-analysis.

Authors:  Ashutosh Nath Aggarwal; Ritesh Agarwal; Sahajal Dhooria; Kuruswamy Thurai Prasad; Inderpaul Singh Sehgal; Valliappan Muthu
Journal:  PLoS One       Date:  2022-07-11       Impact factor: 3.752

2.  Comparison of GeneXpert cycle threshold values with smear microscopy and culture as a measure of mycobacterial burden in five regional referral hospitals of Uganda- A cross-sectional study.

Authors:  Irene Najjingo; Winters Muttamba; Bruce J Kirenga; Joanitah Nalunjogi; Ritah Bakesiima; Francis Olweny; Pastan Lusiba; Achilles Katamba; Moses Joloba; Willy Ssengooba
Journal:  PLoS One       Date:  2019-05-15       Impact factor: 3.240

Review 3.  Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia.

Authors:  Ayinalem Alemu; Mengistu Tadesse; Getachew Seid; Helina Mollalign; Kirubel Eshetu; Waganeh Sinshaw; Yeshiwork Abebaw; Misikir Amare; Biniyam Dagne; Getu Diriba; Bazezew Yenew; Melak Getu; Betselot Zerihun
Journal:  BMC Infect Dis       Date:  2020-01-30       Impact factor: 3.090

4.  The Role of Cartridge-Based Nucleic Acid Amplification Test (CBNAAT), Line Probe Assay (LPA), Liquid Culture, Acid-Fast Bacilli (AFB) Smear and Histopathology in the Diagnosis of Osteoarticular Tuberculosis.

Authors:  S Abhimanyu; Anil K Jain; V P Myneedu; Vinod K Arora; Manish Chadha; Rohit Sarin
Journal:  Indian J Orthop       Date:  2021-01-25       Impact factor: 1.251

5.  Application value of tissue tuberculosis antigen combined with Xpert MTB/RIF detection in differential diagnoses of intestinal tuberculosis and Crohn's disease.

Authors:  Baoying Fei; Lin Zhou; Yu Zhang; Linhe Luo; Yuanyuan Chen
Journal:  BMC Infect Dis       Date:  2021-05-28       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.